<DOC>
	<DOCNO>NCT00036842</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat men germ cell cancer respond previous treatment .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Men With Germ Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate ( confirm complete partial response ) men refractory testicular extragonadal germ cell malignancy treat arsenic trioxide . - Determine overall progression-free survival patient treated drug . - Determine qualitative quantitative toxic effect drug patient . - Assess biomarker response rate patient elevate biomarkers treat drug . OUTLINE : This multicenter study . Patients receive arsenic trioxide IV 1-2 hour day 1-5 . Courses repeat every 28 day 3 year absence disease progression unacceptable toxicity . Patients achieve confirm complete partial response receive 3 additional course past response . Patients follow every 2 month 3 year disease progression . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 10-40 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm testicular extragonadal germ cell cancer Refractory disease , define least 1 follow criterion : Disease progression within 4 week cisplatincontaining regimen Progression define appearance new progression know locally advanced metastatic disease rise tumor marker ( betahuman chorionic gonadotropin ( betaHCG ) alpha fetoprotein ( AFP ) ) least 50 % relative nadir When evidence germ cell progression recurrence study entry appearance new lesion absence tumor marker elevation , biopsy require confirm diagnosis Disease recurrence least 2 chemotherapy regimen , one include highdose therapy ( chemotherapy stem cell support ) Disease recurrence least 2 chemotherapy regimen eligible highdose therapy At least 1 follow : Unidimensionally measurable disease Soft tissue , irradiate within past 2 month , consider measurable Elevated betaHCG ( 20 mIU/mL ) AFP great 2 time upper limit normal PATIENT CHARACTERISTICS : Age : 16 Sex : Male Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 WBC least 3,000/mm^3 Hepatic : Bilirubin le 2.5 time upper limit normal ( ULN ) SGOT le 5 time ULN Alkaline phosphatase less 5 time ULN Renal : Creatinine great 2.5 time ULN OR Creatinine clearance least 40 mL/min Potassium normal Magnesium normal No renal dialysis Cardiovascular : No prior torsades de pointestype ventricular arrhythmia No prolong QT interval ( great 450 msec ) ECG presence normal potassium magnesium Other : Fertile patient must use effective contraception No active serious infection control antibiotic No known hypersensitivity arsenic No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer stage I II disease complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics More 28 day since prior cytotoxic agent Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 28 day since prior radiotherapy recover Surgery : Not specify Other : More 28 day since prior experimental agent No concurrent plan drug know prolong QT interval</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
</DOC>